SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 93 filers reported holding SEELOS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $37,150 | -69.8% | 201,900 | +96.4% | 0.00% | – |
| Q2 2023 | $122,847 | +84.0% | 102,800 | +6.4% | 0.00% | – |
| Q1 2023 | $66,770 | -70.0% | 96,600 | -70.5% | 0.00% | – |
| Q4 2022 | $222,448 | -63.1% | 327,611 | -44.1% | 0.00% | – |
| Q3 2022 | $603,000 | -14.3% | 585,547 | -43.5% | 0.00% | – |
| Q2 2022 | $704,000 | +124.9% | 1,035,564 | +176.9% | 0.00% | – |
| Q1 2022 | $313,000 | +25.2% | 373,967 | +144.1% | 0.00% | – |
| Q4 2021 | $250,000 | -50.6% | 153,214 | -27.1% | 0.00% | – |
| Q3 2021 | $506,000 | -8.3% | 210,233 | +0.6% | 0.00% | – |
| Q2 2021 | $552,000 | -47.9% | 208,980 | -3.6% | 0.00% | – |
| Q1 2021 | $1,059,000 | +761.0% | 216,813 | +178.6% | 0.00% | – |
| Q4 2020 | $123,000 | +547.4% | 77,814 | +280.3% | 0.00% | – |
| Q3 2020 | $19,000 | +11.8% | 20,459 | -42.3% | 0.00% | – |
| Q1 2020 | $17,000 | -41.4% | 35,450 | +169.2% | 0.00% | – |
| Q2 2019 | $29,000 | – | 13,167 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |